Rising demand for GLP-1 receptor agonists—semaglutide and tirzepatide—is colliding with systemic insurance barriers, leaving eligible patients with obesity struggling to access life-saving weight management treatments.
New research shows that prescription gaps are widening by race, socioeconomic status, and insurance coverage, sharply limiting access for vulnerable populations across the United States.
Clinical Realities of GLP-1 Accessibility
- The Mechanism: GLP-1s mimic hormones that regulate insulin, blood sugar, and appetite, helping patients achieve weight loss that is often unattainable through diet and exercise alone.
- The Access Gap: Despite being FDA-approved for chronic weight management, these drugs remain difficult to obtain for patients without type 2 diabetes due to restrictive insurance benefit designs.
- Structural Barriers: Administrative burdens, such as complex prior authorization requirements, continue to disproportionately affect under-resourced clinics, creating a two-tier system of care.
Widening Disparities in Prescription Trends
A study published in Health Affairs Scholar by researchers at the Boston University School of Public Health (BUSPH) analyzed claims data for 512,389 commercially insured patients. While the percentage of eligible patients filling prescriptions rose from 1.9% in 2021 to 16.6% by 2025, the growth was not uniform. Data shows that men, younger and older adults, and Black or Hispanic patients faced lower rates of prescription fulfillment.
The study found that patients treated at clinics in lower-socioeconomic status (SES) neighborhoods had 35% lower odds of receiving these medications by 2024–2025, up from a 15% gap earlier in the study period. “We have better treatments for obesity than ever, but access to them hasn’t caught up,” said Dr. Andrew Stokes, the study’s senior author.
“It is much easier for people with diabetes to get these drugs covered by insurance. But for people living with overweight or obesity, coverage is very difficult to obtain—even when they qualify.”

“GLP-1 receptor agonists are moving into routine care very quickly, but without deliberate action, these drugs risk widening the health inequities that obesity already reflects,” said Dr. Minh Trung Le, study lead and corresponding author, a research data analyst in the Department of Global Health at BUSPH.
Employer and Medicaid Coverage for GLP-1s Declines Sharply
Access is further complicated by shifting payer policies. According to Newser, a survey by the Business Group on Health revealed that the share of large employers covering GLP-1s for weight loss fell from 72% in 2025 to 60% this year. Companies including Starbucks, UPS, and Comcast have cited rising costs as a primary driver for scaling back benefits, leaving many employees without affordable options.

State-level Medicaid programs have also seen dramatic changes. As reported by News-Medical, research published in JAMA found that quarterly prescriptions for weight-loss-approved GLP-1s plummeted by 84% in California, New Hampshire, Pennsylvania, and South Carolina after those states withdrew Medicaid coverage on January 1, 2026. In Pennsylvania alone, the prescription rate fell by 95.5% following the policy change.
| Insurance Setting | Trend Observation |
|---|---|
| Large Employers | Coverage dropped from 72% (2025) to 60% (2026) |
| Medicaid (States ending coverage) | 84% decline in quarterly prescriptions |
| Commercial (Low-SES clinics) | 35% lower odds of prescription (2024-2025) |
Contraindications and Side Effects Require Medical Supervision
GLP-1 receptor agonists are potent pharmacological agents that require medical supervision. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should avoid these medications.
Common side effects include gastrointestinal distress, such as nausea, vomiting, and diarrhea. Patients currently using these therapies should consult their healthcare provider immediately if they experience symptoms of pancreatitis, such as severe abdominal pain radiating to the back, or signs of gallbladder disease.

The Future of Obesity Care
The current struggle for access highlights a fundamental disagreement regarding the nature of obesity. Experts argue that viewing obesity as a chronic disease, rather than a lifestyle failure, is essential for equitable treatment. “A doctor would never tell a patient with diabetes or with heart disease that their only option is to ‘modify their dietary regimens’ or ‘exercise more,'” Dr. Stokes told Medical Xpress.
While some emerging oral small-molecule treatments, such as orforglipron, may offer more cost-effective production in the future, the immediate challenge remains the integration of these therapies into standard insurance benefit designs. As Dr. Katherine Hempstead of the Robert Wood Johnson Foundation noted, the reliance on out-of-pocket payments for those with high socioeconomic resources risks institutionalizing health inequities that the medical community is currently ill-equipped to resolve.
The Boston University School of Public Health was established in 1976 as a program for working medical professionals, initially offering only evening classes to accommodate their schedules. Since officially becoming a school of the university in 1979, it has grown significantly, now supporting a research portfolio valued at more than $180 million and enrolling students from more than 43 countries.
Based in the historic Talbot Building—a Gothic Revival structure completed in 1876 that originally housed the Massachusetts Homeopathic Hospital—the school has evolved from its early focus on practical health delivery systems to a comprehensive institution consistently ranked among the top public health schools in the United States.
“These important results show how emerging patterns of GLP-1 access reflect the inequity and fragmentation of our overall health care system, where access to affordable care is all too often a function of where you work, what state you live in or how much money you have,” said Dr. Katherine Hempstead, senior policy officer at the Robert Wood Johnson Foundation.
References
- Le, M. T., & Stokes, A. C. (2026). Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment. Health Affairs Scholar. https://doi.org/10.1093/haschl/qxag255
- Shuey, B., et al. (2026). Glucagon-like Peptide-1 utilization following withdrawal of medicaid coverage for weight loss. JAMA.
- American Medical Association (AMA) policy on obesity as a disease.